FLT3基因在各种血液肿瘤患者中的表达及其临床意义

目的 为进一步研究各种类型血液肿瘤患者FLT3基因的表达情况。方法 采用多聚酶链反应（PCR）方法检测103例初治AML、76例急性淋巴细胞白血病（ALL）、53例慢性粒细胞白血病（CML）慢性期、31例CML急变期、11例慢性淋巴细胞白血病（CLL）、36骨髓增生异常综合征（MDS）患者、9例多发性骨髓瘤（MM）及13例伴有骨髓侵犯非霍奇金淋巴瘤（NHL）患者FLT3基因表达情况。结果 FLT3基因在各种血液肿瘤表达为AML患者90．3％（93／103）、ALL患者60．5％（46／76）、CML慢性期患者5．7％（3／53）、CML急变期患者61．3％（19／31）、CLL患者9．1％（1／11）、MDS患者25．0％（9／36）。9例MM和7例伴有骨髓浸润NHL患者均未发现FLT3基因表达。AML患者FLT3基因检测阳性率显著高于其他类型白血病患者，CML急变期患者FLT3基因检测阳性率显著高于慢性期患者，ALL患者FLT3基因检测阳性率显著高于CLL患者。结论 各种类型白血病均可出现FLT3基因的表达，但表达率不同，以AML最高，而CLL和CML慢性期最低，FLT3基因在急性髓系白血病恶性克隆的增殖和维持中起重要作用。

The expression of FLT3 gene in different hematotogic maligancy patients and it's clinical significance

Objective To analyze the expression of Fms-like tyrosine kinase 3(FLT3)gene in different hematologic malignancy patients. Methods Polymerase chain reaction(PCR)was used to detect FLT3 gene expression in 103 patients of AML cases, 63 ALL, 53 CML in chronic phase, 31 CML in blast crisis, 11 CLL, 36 MDS, 9 MM and 13 NHL with marrow infiltration. Results The expression of FLT3 gene was detected in 93.3% (93/103) of AML, in 60.5% (46/76) of ALL, in 5.7% (3/53) of CML in chronic phase, in 61.3%(19/31) of CML in blast crisis, in 9.1%(1/11) of CLL, and in 25.0% (9/36) of MDS. FLT3 gene expression not detected in MM and NHL. The positive rate of FLT3 gene was significantly higher in AML than that in the other types of leukemia (P<0.005),The rate was significantly higher in CML in blast crisis than that in CML in chronic phase, while the rate was significantly higher in ALL than that in CLL. Conclusions FLT3 gene is expressed in different types of leukemia. The expression rate is the highest in AML and the lowest in CLL and CML in chronic phase. FLT3 gene plays an important role in proliferation and survival of malignant clone of AML.